Literature DB >> 2658210

Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough-level monitoring.

J Grevel1, M S Welsh, B D Kahan.   

Abstract

Trough levels (TL) of cyclosporine (CS) measured in serum by the polyclonal radioimmunoassay (SR) are useful for dissecting the etiology of clinical events, but they are a poor guide to dosage adjustments. In renal transplant patients immunosuppressed by low doses of prednisone and CS given orally, once-a-day TL (24-h) monitoring was replaced by area under the curve (AUC) monitoring, i.e., measuring the area under the concentration (SR)-time curve from seven blood samples (0, 2, 4, 6, 10, 14, and 24 h) at clinical steady state, which was reached on the 3rd day after a change in the oral dose rate. The therapeutic target was an average concentration at steady state (Css av) of 200 ng/ml during the first 6 months after transplantation and 150 ng/ml thereafter. The Css av was calculated by dividing the AUC by the dosing interval (24 h). Two findings demonstrated the superiority of AUC monitoring over TL monitoring. First, in 71 paired observations AUC but not TL was significantly correlated with the dose expressed as total mg (r = 0.381, p = 0.001) or mg/kg body weight (r = 0.538, p = 0.0001). Second, after adjusting (n = 26) the oral dose rate (to achieve the therapeutic target) the absolute error (i.e., deviation from the target) in the AUC observation (15%) was significantly (p = 0.0005) smaller than in the TL observation (36%). Monitoring AUC at clinical steady state reduced the number of dosage adjustments by a factor of 3.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2658210

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  17 in total

1.  Application of a gamma model of absorption to oral cyclosporin.

Authors:  J Debord; E Risco; M Harel; Y Le Meur; M Büchler; G Lachâtre; C Le Guellec; P Marquet
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 2.  Optimisation of immunosuppressive therapy using pharmacokinetic principles.

Authors:  J Grevel
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

3.  Prediction of acute graft rejection in renal transplantation: the utility of cyclosporine blood concentrations.

Authors:  J Grevel; K L Napoli; M S Welsh; N E Atkinson; B D Kahan
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

4.  Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients.

Authors:  Hélène Bourgoin; Gilles Paintaud; Matthias Büchler; Yvon Lebranchu; Elisabeth Autret-Leca; France Mentré; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

Review 5.  Therapeutic drug monitoring in pregnancy: rationale and current status.

Authors:  C Knott; F Reynolds
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 6.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 7.  New frontiers in immunosuppression.

Authors:  Luke J Benvenuto; Michaela R Anderson; Selim M Arcasoy
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

8.  Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants.

Authors:  Frédéric Leger; Jean Debord; Yann Le Meur; Annick Rousseau; Mathias Büchler; Gérard Lachâtre; Gilles Paintaud; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 9.  Pharmacokinetic and pharmacodynamic data and models in clinical trials.

Authors:  J L Steimer; M E Ebelin; J Van Bree
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

10.  Cyclosporin therapeutic drug monitoring--an established service revisited.

Authors:  Raymond G Morris
Journal:  Clin Biochem Rev       Date:  2003-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.